Fannie Mae, Freddie Mac shares tumble after conservatorship comments
MILAN - Johnson & Johnson (NYSE:JNJ) reported Friday that its experimental dual-targeting CAR T-cell therapy demonstrated high response rates in patients with relapsed or refractory large B-cell lymphoma (LBCL).
The Phase 1b study of JNJ-90014496, a therapy designed to target both CD19 and CD20 proteins on cancer cells, showed complete response rates of 75-80% among evaluable patients at the recommended Phase 2 dose, according to data presented at the 2025 European Hematology Association Congress. This development adds to J&J’s extensive pharmaceutical portfolio, which has helped generate annual revenues exceeding $89 billion.
Among patients who received one prior line of therapy, the objective response rate was 100% with an 80% complete response rate. For those with two or more prior treatments, the objective response rate was 92% with a 75% complete response rate.
The therapy demonstrated a favorable safety profile with no Grade 3 or 4 cytokine release syndrome observed in the recommended Phase 2 dose group. The most common serious side effect was neutropenia, affecting 72% of patients.
"The data presented today show encouraging clinical activity and promising safety," said Krish Patel, Director of Lymphoma Research at Sarah Cannon Research Institute and principal study investigator, in the press release.
LBCL is an aggressive blood cancer that originates in the lymphatic system, with diffuse large B-cell lymphoma (DLBCL) being its most common form. Current treatments achieve long-term remission in only about 40% of patients.
The therapy is being developed under a collaboration agreement between Johnson & Johnson and AbelZeta Inc. initiated in 2023.
In other recent news, Johnson & Johnson presented promising results from several studies across different therapeutic areas. The company reported new data from a Phase 1b study of its investigational drug bleximenib, showing an overall response rate of 82% in patients with relapsed or refractory acute myeloid leukemia and 90% in newly diagnosed patients. In another development, the CARTITUDE-1 study revealed that 33% of patients with relapsed or refractory multiple myeloma treated with CARVYKTI experienced progression-free survival for five years or longer. Further data from the CARTITUDE-4 study showed improved progression-free and overall survival benefits across various subgroups.
Additionally, Johnson & Johnson’s Tremfya demonstrated significant reduction in joint structural damage progression in psoriatic arthritis patients, with more than 40% achieving significant improvement in symptoms. The company also revealed initial results from a Phase 1 trial of its trispecific antibody JNJ-5322, with an overall response rate of 86.1% in multiple myeloma patients at the recommended dose. In corporate news, Daniel Pinto, President of JPMorgan Chase, has been elected to the Board of Directors, bringing over three decades of financial expertise to the company. These developments highlight Johnson & Johnson’s ongoing efforts to advance treatment options in oncology and other therapeutic areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.